<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2168">
  <stage>Registered</stage>
  <submitdate>7/11/2008</submitdate>
  <approvaldate>7/11/2008</approvaldate>
  <nctid>NCT00788333</nctid>
  <trial_identification>
    <studytitle>Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast Cancer</studytitle>
    <scientifictitle>A Phase I/II Trial of BMS-754807 in Combination With Trastuzumab (Herceptin®) in Subjects With Advanced or Metastatic Her-2-positive Breast Cancer</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>EUDRACT #: 2009-013766-78</secondaryid>
    <secondaryid>CA191-004</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Breast Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - BMS-754807
Treatment: drugs - trastuzumab (Herceptin®)

Experimental: A - Combination


Treatment: drugs: BMS-754807
Tablets, Oral, Dose escalation to MTD, then MTD to response/EOT, once daily, Varies - treatment is continued to disease progression or MD/subject/Sponsor decision to stop

Treatment: drugs: trastuzumab (Herceptin®)
IV solution, IV, 4mg/kg Day 1 loading dose, 2mg/kg once weekly, Varies - treatment is continued to disease progression or MD/subject/Sponsor decision to stop

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The dose escalation portion will determine the MTD and recommended Phase 2 dose or dose range of BMS-754807 when administered orally on a daily schedule in combination with trastuzumab administered at standard doses IV on a weekly basis</outcome>
      <timepoint>Every 30 days until MTD is reached</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Assess anti-tumor activity of combination at MTD of BMS-754807 (dose expansion cohort)</outcome>
      <timepoint>Every 8 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Evaluate safety and tolerability of the combination regimen</outcome>
      <timepoint>Ongoing</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assess effect of combination therapy on glucose metabolism</outcome>
      <timepoint>At 30 days, then every 8 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Explore whether co-medication with oral anti-hyperglycemic agent can enable adequate tolerability of the combination therapy if BMS-754807 induces hyperglycemia</outcome>
      <timepoint>Ongoing</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Obtain BMS-754807 plasma concentrations vs time data for future population PK analysis</outcome>
      <timepoint>Days, 1,8,15,22</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>For additional information on this trial, please call (910) 558-2913

        

          -  Subjects with locally advanced or metastatic Her-2-positive breast cancer who have
             failed at least one trastuzumab containing regimen. Prior treatment with other
             Her-2-targeted agents (e.g. lapatinib, pertuzumab, trastuzumab DM-1 etc.) is allowed

          -  Histologic or cytologic diagnosis of Her-2-positive breast cancer

          -  ECOG status 0 - 1</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Symptomatic brain metastasis

          -  Any condition requiring chronic use of steroids

          -  Any disorder with dysregulation of glucose homeostasis (history of Type 1 or 2
             Diabetes Mellitus or prediabetic symptoms

          -  History of glucose intolerance

          -  Women of child-bearing potential unwilling or unable to use acceptable contraception
             methods</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1/Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>40</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/11/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA,VIC</recruitmentstate>
    <hospital>Local Institution - Kurralta Park</hospital>
    <hospital>Local Institution - Frankston</hospital>
    <hospital>Local Institution - Geelong</hospital>
    <postcode>5037 - Kurralta Park</postcode>
    <postcode>3199 - Frankston</postcode>
    <postcode>3220 - Geelong</postcode>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Miskolc</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Tyne And Wear</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bristol-Myers Squibb</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a Phase I/II study to evaluate the safety profile, tolerability, pharmacokinetics and
      pharmacodynamics following daily oral doses of 50 to 200 mg of BMS-754807 in combination with
      trastuzumab (Herceptin®) in subjects with advanced or metastatic Her-2-positive breast
      cancer. In addition, the study is expected to identify the recommended dose or dose range of
      BMS-754807 in combination with trastuzumab for Phase II studies and provide preliminary
      evidence of anti-tumor activity in Her-2-positive breast cancer subjects after trastuzumab
      failure</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00788333</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bristol-Myers Squibb</name>
      <address>Bristol-Myers Squibb</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>